# S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

> **NCT00234039** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 58 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00234039
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2011-11
- **Final completion:** 2013-04
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2016-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234039, "S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00234039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*